Endogenous Galectin-9 suppresses apoptosis in human rheumatoid arthritis synovial fibroblasts

Mark Pearson, Magdalena Bik, Caroline Ospelt, Amy Naylor, Corinna Wehmeyer, Simon Jones, Christopher Buckley, Steffen Gay, Andrew Filer, Janet Lord

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)
152 Downloads (Pure)


Galectin-9 (Gal9) has been postulated to have anti-inflammatory properties based on the ability of exogenous Gal9 to induce apoptosis in synovial fibroblasts in animal models of rheumatoid arthritis (RA). Here we aimed to assess the potential role of endogenous Galectins, including Gal9, in the inflammatory pathology of the RA synovium in humans. Firstly expression of Galectins 1–9 was determined in synovial fibroblasts (RASF) and dermal fibroblasts (DF) isolated from RA patients, the latter representing a non-inflamed site. We then further challenged the cells with pro-inflammatory TLR agonists and cytokines and assessed Galectin expression. Gal9 was found to be differentially and abundantly expressed in RASF compared to DF. Agonists of TLR3 and TLR4, along with IFNgamma were also found to induce Gal9 expression in RASF. siRNA was then used to knock-down Gal9 expression in RASF and the effects of this on apoptosis and cell viability were assessed. Increased apoptosis was observed in RASF following Gal9 knock-down. We conclude that, unlike exogenous Gal9, endogenous Gal9 is protective against apoptosis and enhances synovial fibroblast viability suggesting that its role in RA is both pathogenic and pro-inflammatory.
Original languageEnglish
Article number12887
Number of pages8
JournalScientific Reports
Publication statusPublished - 27 Aug 2018


Dive into the research topics of 'Endogenous Galectin-9 suppresses apoptosis in human rheumatoid arthritis synovial fibroblasts'. Together they form a unique fingerprint.

Cite this